CenterBook Partners’s Royalty Pharma RPRX Stock Holding History

CenterBook Partners’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.5M	Sell	25,729 -5,366	-17%	-$317K	0.07%	352
2026 Q2	$1.74M	Sell	31,095 -126,082	-80%	-$6.56M	0.09%	260
2026 Q1	$7.54M	Buy	157,177 +86,965	+124%	+$3.81M	0.41%	60
2025 Q4	$2.71M	Sell	70,212 -18,104	-20%	-$690K	0.13%	210
2025 Q3	$3.12M	Sell	88,316 -70,706	-44%	-$2.56M	0.15%	189
2025 Q2	$5.73M	Buy	159,022 +96,015	+152%	+$3.18M	0.32%	85
2025 Q1	$1.96M	Sell	63,007 -41,728	-40%	-$1.32M	0.12%	199
2024 Q4	$2.67M	Sell	104,735 -113,525	-52%	-$3.01M	0.16%	166
2024 Q3	$6.17M	Buy	+218,260	New	+$6.05M	0.38%	81

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $127B AUM 33.25% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

CenterBook Partners's RPRX Position: Q3 2026 in Review

CenterBook Partners reduced its Royalty Pharma (RPRX) stake by 17% in Q3 2026, selling an estimated $317K and leaving 25,729 shares worth $1.5M. The position accounts for 0.07% of the portfolio, ranked #352.

CenterBook Partners first reported a position in RPRX in Q3 2024 and has held it in 9 quarters since. The position peaked at $7.54M in Q1 2026. 393 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

CenterBook Partners held 25,729 shares of Royalty Pharma worth $1.5M as of Q3 2026.
CenterBook Partners sold 5,366 Royalty Pharma shares in Q3 2026, an estimated $317K.
Royalty Pharma made up 0.07% of CenterBook Partners's portfolio in Q3 2026, its #352 holding.
CenterBook Partners first reported a position in Royalty Pharma in Q3 2024 and has held it in 9 quarters since.
CenterBook Partners's Royalty Pharma position peaked at $7.54M in Q1 2026.
393 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on CenterBook Partners's 13F filing for Q3 2026, filed 2 Nov 2026.